国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2010年
5期
560-562
,共3页
乳腺肿瘤%多西紫杉醇%吉西他滨%联合化疗
乳腺腫瘤%多西紫杉醇%吉西他濱%聯閤化療
유선종류%다서자삼순%길서타빈%연합화료
Breast cancer%Docetaxel%Gemcitabine%Combined chemotherapy
目的 观察多西紫杉醇(DXL)联合吉西他滨(Gemcitabine)方案治疗蒽环类耐药性晚期乳腺癌的临床疗效与毒副作用.方法 将我院2004年1月-2008年6月收治的蒽环类耐药性晚期乳腺癌患者85例,随机分成两组,多西紫杉醇治疗(DT)组42例,多西紫杉醇联合吉西他滨治疗(DGT)组43列.DT组用多西紫杉醇75 mg/m~2,静滴,第1天.21d为1周期;DGT组用多西紫杉醇75 mg/m~2,静滴,第1天,吉西他滨1000mg/m~2,静滴,第1天和第8天,21d为1周期.两组中位化疗周期数均为6周期.检测指标为疗效、无进展生存期(progression free survival,PFS).结果 DT组和DGT组的中位无进展生存期分别为(6.78±0.54)个月与(9.69±0.65)个月,两者比较差异有显著性(P<0.05).DT组疗效为总有效率(CR+PR)为47.6%.DGT组总有效率(CR+PR)为62.8%,两者比较差异有显著性(P<0.05).两组的主要毒副作用为胃肠道反应和骨髓抑制反应.结论 多西紫杉醇联合青西他滨化疗方案治疗蒽环类耐药的晚期乳腺癌疗效好,无交叉耐药性,不良反应轻,是蒽环类耐药性乳腺癌的有效治疗方案.
目的 觀察多西紫杉醇(DXL)聯閤吉西他濱(Gemcitabine)方案治療蒽環類耐藥性晚期乳腺癌的臨床療效與毒副作用.方法 將我院2004年1月-2008年6月收治的蒽環類耐藥性晚期乳腺癌患者85例,隨機分成兩組,多西紫杉醇治療(DT)組42例,多西紫杉醇聯閤吉西他濱治療(DGT)組43列.DT組用多西紫杉醇75 mg/m~2,靜滴,第1天.21d為1週期;DGT組用多西紫杉醇75 mg/m~2,靜滴,第1天,吉西他濱1000mg/m~2,靜滴,第1天和第8天,21d為1週期.兩組中位化療週期數均為6週期.檢測指標為療效、無進展生存期(progression free survival,PFS).結果 DT組和DGT組的中位無進展生存期分彆為(6.78±0.54)箇月與(9.69±0.65)箇月,兩者比較差異有顯著性(P<0.05).DT組療效為總有效率(CR+PR)為47.6%.DGT組總有效率(CR+PR)為62.8%,兩者比較差異有顯著性(P<0.05).兩組的主要毒副作用為胃腸道反應和骨髓抑製反應.結論 多西紫杉醇聯閤青西他濱化療方案治療蒽環類耐藥的晚期乳腺癌療效好,無交扠耐藥性,不良反應輕,是蒽環類耐藥性乳腺癌的有效治療方案.
목적 관찰다서자삼순(DXL)연합길서타빈(Gemcitabine)방안치료은배류내약성만기유선암적림상료효여독부작용.방법 장아원2004년1월-2008년6월수치적은배류내약성만기유선암환자85례,수궤분성량조,다서자삼순치료(DT)조42례,다서자삼순연합길서타빈치료(DGT)조43렬.DT조용다서자삼순75 mg/m~2,정적,제1천.21d위1주기;DGT조용다서자삼순75 mg/m~2,정적,제1천,길서타빈1000mg/m~2,정적,제1천화제8천,21d위1주기.량조중위화료주기수균위6주기.검측지표위료효、무진전생존기(progression free survival,PFS).결과 DT조화DGT조적중위무진전생존기분별위(6.78±0.54)개월여(9.69±0.65)개월,량자비교차이유현저성(P<0.05).DT조료효위총유효솔(CR+PR)위47.6%.DGT조총유효솔(CR+PR)위62.8%,량자비교차이유현저성(P<0.05).량조적주요독부작용위위장도반응화골수억제반응.결론 다서자삼순연합청서타빈화료방안치료은배류내약적만기유선암료효호,무교차내약성,불량반응경,시은배류내약성유선암적유효치료방안.
Objective To observe the curative effect and safety of combination chemotherapy of docetaxel (DXL) and gemcitabine for anthracycline (ANT)-resistant advanced breast cancer (ABC). Methods From January 2004 to December 2008 in our hospital, 85 patients with ANT-resistant advanced breast cancer were randomly divided into docetaxel treated group (DT,42 cases) and docetaxel (DXL) combined with gemcitabine treated group (DGT, 43 cases). In the DT group, patients were treated with docetaxel 75 mg/m~2 for day 1 every three weeks. In the DGT group, patients were treated with docetaxel 75 mg/m~2 for day 1 and gemcitabine 1000 mg/m~2 for day 1 and day 8 every three weeks. The median number of cycles was six. Comparison of curative effect and progression-free survival (PFS) were the primary objective. Results Median PFS was 6.78 ± 0.54 months for DT group and 9.69±0.65 for DGT group (P<0.05). The overall response rate was 47.6% for DT group and 62.8% for DGT group (P<0.05). The main side effects were gastrointestinal and hematologic toxicities. Conclusion The combination chemotherapy of docetaxel (DXL) and gemcitabine is an effective mean for the treatment of anthracycline-resistant advanced breast cancer patient with an acceptable toxicity, and may be a therapeutic alternative after anthracycline regimen failed.
